Login / Signup

Establishment of a Pseudovirus Platform for Neuraminidase Inhibiting Antibody Analysis.

Yulia A DeshevaNadezhda PetkovaIgor LosevDmitry GuzhovAlexey GoYu-Chan ChaoChih-Hsuan Tsai
Published in: International journal of molecular sciences (2023)
Neuraminidase (NA)-based immunity to influenza can be useful for protecting against novel antigenic variants. To develop safe and effective tools to assess NA-based immunity, we generated a baculovirus-based pseudotyped virus, N1-Bac, that expresses the full-length NA of the influenza A/California/07/2009 (H1N1)pdm09 strain. We evaluated the level of NA-inhibiting (NI) antibodies in the paired blood sera of influenza patients by means of an enzyme-linked lectin assay (ELLA) using the influenza virus or N1-Bac. Additionally, we evaluated the level of NA antibodies by means of the enzyme-linked immunosorbent assay (ELISA) with an N1-expressing Sf21 culture. We detected a strong correlation between our results from using the influenza virus and NA-Bac pseudoviruses to detect NI antibodies and a medium-strong correlation between NI antibodies and NA antibodies determined by an N1-cell ELISA, indicating that baculovirus-based platforms can be successfully used to evaluate NI or NA antibodies. Furthermore, animal experiments showed that immunization with N1-Bac protected against infection with a drift variant of the A/H1N1pdm09 influenza virus. Our results demonstrate that recombinant baculovirus can be an effective influenza pseudotype to evaluate influenza serologic immunity and protect against influenza virus infection.
Keyphrases
  • high throughput
  • signaling pathway
  • stem cells
  • sars cov
  • cell therapy
  • coronavirus disease
  • copy number
  • genome wide
  • patient reported outcomes
  • cell free